PMID- 36139689
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220928
IS  - 2072-6694 (Print)
IS  - 2072-6694 (Electronic)
IS  - 2072-6694 (Linking)
VI  - 14
IP  - 18
DP  - 2022 Sep 19
TI  - The Evolving Interplay of SBRT and the Immune System, along with Future 
      Directions in the Field.
LID - 10.3390/cancers14184530 [doi]
LID - 4530
AB  - In this commentary, we describe the potential of highly ablative doses utilizing 
      Stereotactic Body Radiation Therapy (SBRT) in single or few fractions to enhance 
      immune-responsiveness, how timing of this approach in combination with 
      immune-checkpoint inhibitors may augment treatment-effect, and whether 
      Personalized Ultrafractionated Stereotactic Adaptive Radiation Therapy (PULSAR) 
      is an avenue for future advancement in the continued endeavor to foster a 
      systemic effect of therapy beyond the radiation treatment field. The ablative 
      potential of SBRT may support an increase in tumor-antigen presentation, 
      enhancement of immune-stimulatory components, and an improvement in 
      tumor-microenvironment immune cell infiltration. Furthermore, the latest 
      advancement of ablative radiation delivery is PULSAR-based therapy, whereby 
      ablative doses are delivered in pulses of treatment that may be several weeks 
      apart, combined with adaptive treatment to tumor changes across time. The 
      benefits of this novel approach include the ability to optimize direct tumor 
      control by assessment of tumor size and location via dedicated imaging acquired 
      prior to each delivered pulse, and further potentiation of immune recognition 
      through combination with concurrent immune-checkpoint blockade.
FAU - Miljanic, Mihailo
AU  - Miljanic M
AD  - Department of Radiation Oncology, University of Texas Southwestern Medical 
      Center, Dallas, TX 75390, USA.
FAU - Montalvo, Steven
AU  - Montalvo S
AD  - Department of Radiation Oncology, University of Texas Southwestern Medical 
      Center, Dallas, TX 75390, USA.
FAU - Aliru, Maureen
AU  - Aliru M
AD  - Department of Radiation Oncology, University of Texas Southwestern Medical 
      Center, Dallas, TX 75390, USA.
FAU - Song, Tidie
AU  - Song T
AD  - Department of Radiation Oncology, University of Texas Southwestern Medical 
      Center, Dallas, TX 75390, USA.
FAU - Leon-Camarena, Maria
AU  - Leon-Camarena M
AD  - Department of Internal Medicine, University of Texas at Austin, Austin, TX 78705, 
      USA.
FAU - Innella, Kevin
AU  - Innella K
AD  - Philadelphia College of Osteopathic Medicine, Philadelphia, PA 19131, USA.
FAU - Vujovic, Dragan
AU  - Vujovic D
AD  - Icahn School of Medicine at Mount Sinai, The Mount Sinai Hospital, New York, NY 
      10029, USA.
FAU - Komaki, Ritsuko
AU  - Komaki R
AD  - Emeritus Professor of Radiation Oncology, UT MDACC, Adjunct Professor of 
      Radiation Oncology Baylor College of Medicine, Houston, TX 77030, USA.
FAU - Iyengar, Puneeth
AU  - Iyengar P
AD  - Department of Radiation Oncology, University of Texas Southwestern Medical 
      Center, Dallas, TX 75390, USA.
LA  - eng
PT  - Journal Article
DEP - 20220919
PL  - Switzerland
TA  - Cancers (Basel)
JT  - Cancers
JID - 101526829
PMC - PMC9497192
OTO - NOTNLM
OT  - PULSAR
OT  - SAbR
OT  - SBRT
OT  - SBRT and immunotherapy
OT  - adaptive radiation therapy
OT  - immunotherapy in combination with radiation therapy
COIS- The authors declare no conflict of interest.
EDAT- 2022/09/24 06:00
MHDA- 2022/09/24 06:01
PMCR- 2022/09/19
CRDT- 2022/09/23 01:07
PHST- 2022/07/20 00:00 [received]
PHST- 2022/09/04 00:00 [revised]
PHST- 2022/09/15 00:00 [accepted]
PHST- 2022/09/23 01:07 [entrez]
PHST- 2022/09/24 06:00 [pubmed]
PHST- 2022/09/24 06:01 [medline]
PHST- 2022/09/19 00:00 [pmc-release]
AID - cancers14184530 [pii]
AID - cancers-14-04530 [pii]
AID - 10.3390/cancers14184530 [doi]
PST - epublish
SO  - Cancers (Basel). 2022 Sep 19;14(18):4530. doi: 10.3390/cancers14184530.